PT - JOURNAL ARTICLE AU - P R Farina AU - A G Graham AU - C A Homon AU - E S Lazer AU - S E Hattox AU - P S Riska AU - R H Gundel AU - C D Wegner TI - A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor. DP - 1993 May 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 483--489 VI - 265 IP - 2 4099 - http://jpet.aspetjournals.org/content/265/2/483.short 4100 - http://jpet.aspetjournals.org/content/265/2/483.full SO - J Pharmacol Exp Ther1993 May 01; 265 AB - BI-L-226, a 2,6-disubstituted 4-(2-arylethenyl)phenol, is a potent and selective 5-lipoxygenase inhibitor which shows excellent inhibition of antigen-induced leukotriene generation in the lung of cynomolgus monkeys by aerosol administration, although little activity has been observed by the p.o. route. The facile synthesis of the succinate ester BI-L-357, however, results in a prodrug which has p.o. activity between 10 to 30 mg/kg in an ex vivo whole blood model of leukotriene B4 generation in both squirrel and cynomolgus monkeys. In addition, the prodrug is effective in inhibiting pulmonary leukotriene C4 production in antigen-challenged cynomolgus monkeys in the same dose range. Plasma levels of the parent compound in the monkey after p.o. administration of 30 mg/kg are 25-fold higher than the IC50 needed for in vitro inhibition of leukotriene B4 in whole blood. Absolute bioavailability of the parent compound was 50%. The prodrug concept therefore extends the potential of this class of compounds to inflammation sites mediated by 5-lipoxygenase not readily treated by topical administration.